Pigmentary Maculopathy Associated with Chronic Exposure to Pentosan Polysulfate Sodium. 2018

William A Pearce, and Rui Chen, and Nieraj Jain
Emory Eye Center, Emory University Hospital, Atlanta, Georgia.

To describe the clinical features of a unique pigmentary maculopathy noted in the setting of chronic exposure to pentosan polysulfate sodium (PPS), a therapy for interstitial cystitis (IC). Retrospective case series. Six adult patients evaluated by a single clinician between May 1, 2015, and October 1, 2017. Patients were identified by query of the electronic medical record system. Local records were reviewed, including results of the clinical examination, retinal imaging, and visual function assessment with static perimetry and electroretinography. Molecular testing assessed for known macular dystrophy and mitochondrial cytopathy genotypes. Mean best-corrected visual acuity (BCVA; in logarithm of the minimum angle of resolution units), median cumulative PPS exposure, subjective nature of the associated visual disturbance, qualitative examination and imaging features, and molecular testing results. The median age at presentation was 60 years (range, 37-62 years). All patients received PPS for a diagnosis of IC, with a median cumulative exposure of 2263 g (range, 1314-2774 g), over a median duration of exposure of 186 months (range, 144-240 months). Most patients (4 of 6) reported difficulty reading as the most bothersome symptom. Mean BCVA was 0.1±0.18 logarithm of the minimum angle of resolution. On fundus examination, nearly all eyes showed subtle paracentral hyperpigmentation at the level of the retinal pigment epithelium (RPE) with a surrounding array of vitelliform-like deposits. Four eyes of 2 patients showed paracentral RPE atrophy, and no eyes demonstrated choroidal neovascularization. Multimodal retinal imaging demonstrated abnormality of the RPE generally contained in a well-delineated area in the posterior pole. None of the 4 patients who underwent molecular testing of nuclear DNA returned a pathogenic mutation. Additionally, all 6 patients showed negative results for pathogenic variants in the mitochondrial gene MTTL1. We describe a novel and possibly avoidable maculopathy associated with chronic exposure to PPS. Patients reported symptoms of difficulty reading and prolonged dark adaptation despite generally intact visual acuity and subtle funduscopic findings. Multimodal imaging and functional studies are suggestive of a primary RPE injury. Additional investigation is warranted to explore causality further.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010426 Pentosan Sulfuric Polyester A sulfated pentosyl polysaccharide with heparin-like properties. Pentosan Polysulfate,Polypentose Sulfate,BAY-946,Elmiron,Fibrocid,HOE-946,HOE-BAY 946,HOE-BAY-946,Hemoclar,PZ-68,PZ68,Pentosan Polysulfate Sodium,Pentosan Polysulphate Sodium,Pentosane Sulfuric Polyester,Polysulfated Xylan,SP-54,Tavan SP 54,Xylan SP54,Xylan Sulfate,BAY 946,HOE 946,HOE BAY 946,PZ 68,Polyester, Pentosan Sulfuric,Polyester, Pentosane Sulfuric,Polysulfate Sodium, Pentosan,Polysulfate, Pentosan,Polysulphate Sodium, Pentosan,SP 54,SP 54, Tavan,SP54,SP54, Xylan,Sodium, Pentosan Polysulfate,Sodium, Pentosan Polysulphate,Sulfate, Polypentose,Sulfate, Xylan,Sulfuric Polyester, Pentosan,Sulfuric Polyester, Pentosane,Xylan, Polysulfated
D004410 Dyslexia A cognitive disorder characterized by an impaired ability to comprehend written and printed words or phrases despite intact vision. This condition may be developmental or acquired. Developmental dyslexia is marked by reading achievement that falls substantially below that expected given the individual's chronological age, measured intelligence, and age-appropriate education. The disturbance in reading significantly interferes with academic achievement or with activities of daily living that require reading skills. (From DSM-IV) Alexia,Dyslexia, Developmental,Reading Disability, Developmental,Reading Disorder,Reading Disorder, Developmental,Developmental Reading Disorder,Word Blindness,Alexias,Blindness, Word,Blindnesses, Word,Developmental Dyslexia,Developmental Dyslexias,Developmental Reading Disabilities,Developmental Reading Disability,Developmental Reading Disorders,Disabilities, Developmental Reading,Disability, Developmental Reading,Disorder, Developmental Reading,Disorder, Reading,Disorders, Developmental Reading,Disorders, Reading,Dyslexias,Dyslexias, Developmental,Reading Disabilities, Developmental,Reading Disorders,Reading Disorders, Developmental,Word Blindnesses
D004596 Electroretinography Recording of electric potentials in the retina after stimulation by light. Electroretinographies
D005260 Female Females
D005451 Fluorescein Angiography Visualization of a vascular system after intravenous injection of a fluorescein solution. The images may be photographed or televised. It is used especially in studying the retinal and uveal vasculature. Fluorescence Angiography,Fundus Fluorescence Photography,Angiography, Fluorescein,Angiography, Fluorescence,Fluorescence Photography, Fundus,Photography, Fundus Fluorescence
D005820 Genetic Testing Detection of a MUTATION; GENOTYPE; KARYOTYPE; or specific ALLELES associated with genetic traits, heritable diseases, or predisposition to a disease, or that may lead to the disease in descendants. It includes prenatal genetic testing. Genetic Predisposition Testing,Genetic Screening,Predictive Genetic Testing,Predictive Testing, Genetic,Testing, Genetic Predisposition,Genetic Predictive Testing,Genetic Screenings,Genetic Testing, Predictive,Predisposition Testing, Genetic,Screening, Genetic,Screenings, Genetic,Testing, Genetic,Testing, Genetic Predictive,Testing, Predictive Genetic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000925 Anticoagulants Agents that prevent BLOOD CLOTTING. Anticoagulant Agent,Anticoagulant Drug,Anticoagulant,Anticoagulant Agents,Anticoagulant Drugs,Anticoagulation Agents,Indirect Thrombin Inhibitors,Agent, Anticoagulant,Agents, Anticoagulant,Agents, Anticoagulation,Drug, Anticoagulant,Drugs, Anticoagulant,Inhibitors, Indirect Thrombin,Thrombin Inhibitors, Indirect

Related Publications

William A Pearce, and Rui Chen, and Nieraj Jain
February 2020, The Journal of urology,
William A Pearce, and Rui Chen, and Nieraj Jain
November 2023, Retinal cases & brief reports,
William A Pearce, and Rui Chen, and Nieraj Jain
December 2023, The Canadian journal of urology,
William A Pearce, and Rui Chen, and Nieraj Jain
July 2022, British journal of clinical pharmacology,
William A Pearce, and Rui Chen, and Nieraj Jain
January 2022, Survey of ophthalmology,
William A Pearce, and Rui Chen, and Nieraj Jain
November 2020, Investigative ophthalmology & visual science,
William A Pearce, and Rui Chen, and Nieraj Jain
February 2020, Canadian Urological Association journal = Journal de l'Association des urologues du Canada,
William A Pearce, and Rui Chen, and Nieraj Jain
December 2023, The Canadian journal of urology,
William A Pearce, and Rui Chen, and Nieraj Jain
January 2021, Clinical ophthalmology (Auckland, N.Z.),
Copied contents to your clipboard!